Evidence map›Paper›PMID 26606398›Full record

Trial reportArthritis & rheumatology (Hoboken, N.J.)2016

Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Christina Charles-Schoeman, Xiaoyan Wang, Yuen Yin Lee, Ani Shahbazian, Iris Navarro-Millán, Shuo Yang, Lang Chen, Stacey S Cofield, Larry W Moreland, James O'Dell and 4 more

Abstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Optimising Conventional Therapy in Rheumatoid Arthritis.Mediterranean journal of rheumatology · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.Clinical reviews in allergy & immunology · 2020
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Christina Charles-SchoemanUniversity of California, Los Angeles.
Xiaoyan WangUniversity of California, Los Angeles.
Yuen Yin LeeUniversity of California, Los Angeles.
Ani ShahbazianUniversity of California, Los Angeles.
Iris Navarro-MillánUniversity of Alabama at Birmingham.
Shuo YangUniversity of Alabama at Birmingham.
Lang ChenUniversity of Alabama at Birmingham.
Stacey S CofieldUniversity of Alabama at Birmingham.
Larry W MorelandUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
James O'DellUniversity of Nebraska Medical Center, Omaha.
Joan M BathonColumbia University, New York, New York.
Harold PaulusUniversity of California, Los Angeles.
S Louis BridgesUniversity of Alabama at Birmingham.
Jeffrey R CurtisUniversity of Alabama at Birmingham.
University of Alabama at Birmingham · USUniversity of California, Los Angeles · USColumbia University · USUniversity of Nebraska Medical Center · USUniversity of Pittsburgh · US

Funding

UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Mechanisms Linking Joint Inflammation and Atherosclerosis in Rheumatoid ArthritisR01HL123064 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2015 to 2019
$2.7M
Longitudinal Comparative Effectiveness & Safety of Biologics in AutoimmunityR01HS018517 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURTIS, JEFFREY R. · 2009 to 2013
$2.2M
Predictors of Treatment Response in Early Aggressive RAR01AR052658 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BRIDGES, S LOUIS · 2004 to 2007
$1.2M
Ethnic Differences in the Risk of Fracture and Vascular DiseaseK23AR053351 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURTIS, JEFFREY R. · 2007 to 2011
$755k
HDL Function as a Biomarker for Atherosclerotic Risk in Rheumatoid ArthritisK23HL094834 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2009 to 2013
$693k
Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?R21AR057913 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA, REDDY, SRINIVASA T. · 2010 to 2011
$384k
AHRQ HHS R01 HS018517AHRQ HHS R01-HS-018517NCRR NIH HHS 1-UL1-RR-033176NCRR NIH HHS UL1 RR033176NHLBI NIH HHS 5-K23-HL-094834NHLBI NIH HHS K23 HL094834NHLBI NIH HHS R01 HL123064NHLBI NIH HHS R01-HL-123064NIAMS NIH HHS AR-053351NIAMS NIH HHS K23 AR053351NIAMS NIH HHS R01 AR052658NIAMS NIH HHS R01-AR-052658NIAMS NIH HHS R21 AR057913NIAMS NIH HHS R21-AR-057913-01A1
6 · The paper itself

Abstract

objectiveTo evaluate long-term changes in cholesterol levels in patients with early rheumatoid arthritis (RA) who were randomized to begin treatment with methotrexate (MTX) monotherapy, MTX plus etanercept, or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.

methodsLevels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were analyzed in 416 patients participating in the TEAR trial, during 102 weeks of followup. Associations of cholesterol changes with disease activity and drug treatment were evaluated using repeated-measures analysis with mixed-effect linear models to model within-subject covariance over time.

resultsMixed-effect models controlling for traditional cardiovascular (CV) risk factors, TEAR treatment, and baseline prednisone and statin use demonstrated significant inverse associations of RA disease activity with changes in cholesterol over time. Decreases in the 28-joint Disease Activity Score, the C-reactive protein level, or the erythrocyte sedimentation rate were associated with increases in levels of HDL cholesterol, LDL cholesterol, and total cholesterol in all treatment groups (P < 0.001-0.035). Triple therapy was strongly associated with higher levels of HDL cholesterol, lower levels of LDL cholesterol, and higher ratios of total cholesterol:HDL cholesterol (P < 0.001 for all) compared to MTX monotherapy or MTX plus etanercept therapy over the 2-year followup.

conclusionDecreases in RA disease activity over long-term followup were associated with increases in cholesterol levels in patients with early RA treated with either biologic or nonbiologic therapies. The use of triple therapy during 2 years of followup was associated with higher HDL cholesterol levels, lower LDL cholesterol levels, and lower total cholesterol:HDL cholesterol ratios compared to those observed in patients who received MTX monotherapy or MTX plus etanercept combination therapy. Additional studies are needed to assess the effects of these cholesterol changes on CV events in patients with RA.

Indexed as

Arthritis, RheumatoidBlood SedimentationCholesterolC-Reactive ProteinDrug Therapy, CombinationEtanerceptFemaleFollow-Up StudiesHumansLipoproteins, HDLLipoproteins, LDLMaleMethotrexateMiddle AgedCholesterolC-Reactive ProteinEtanerceptLipoproteins, HDLLipoproteins, LDLMethotrexate

Identifiers

PMID26606398
PMCPMC4774543
OpenAlexW2288788648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.